Naveen Pemmaraju: Ph2 CLIA with or without sorafenib for upfront AML therapy.

Naveen Pemmaraju, the Executive Director of Cancer Medicine at the MD Anderson Cancer Center, recently tweeted:

“Brand new paper alert from our group Ph2 CLIA with or without sorafenib for upfront AML therapy led by Tapan Kadia, Hagop Kantarjian, Gautam Borthakur, Naval Daver, Naveen Pemmaraju, Nitin Jain and Musa Yilmaz.”

For the article click here.
Source: Naveen Pemmaraju/Twitter